Evidence map›Paper›PMID 17350960›Full record

ArticleThe Journal of biological chemistry2007

Protein kinase C delta is required for survival of cells expressing activated p21RAS.

Shuhua Xia, Lora W Forman, Douglas V Faller

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Mechanisms of the Regulation and Dysregulation of Glucagon Secretion.Oxidative medicine and cellular longevity · 2020
    Review
  7. Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches.Endocrinology and metabolism clinics of North America · 2018
    Review
  8. Article
  9. Article
  10. Article
  11. Protein Kinase CJournal of the American Society of Nephrology : JASN · 2017
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Targeting the RAS oncogene.Expert opinion on therapeutic targets · 2013
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Shuhua XiaCancer Research Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Lora W Forman
Douglas V Faller
Boston University · USCancer Research Center · US

Funding

Ras Oncoprotein-Targeted Therapy for CancerR01CA112102 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FALLER, DOUGLAS V · 2005 to 2009
$1.7M
Development of a Ras-Targeted Cancer TherapeuticR41CA108100 · NCI · GENE REGULATION LABORATORIES, INC. · PI FALLER, DOUGLAS V · 2004 to 2004
$282k
Development of an Oncogene-Targeted TherapeuticR41CA141908 · NCI · PHOENICIA BIOSCIENCES, INC. · PI FALLER, DOUGLAS V · 2009 to 2009
$271k
NCI NIH HHS CA108100NCI NIH HHS CA112102NCI NIH HHS R01 CA112102NCI NIH HHS R41 CA108100NCI NIH HHS R41 CA141908
6 · The paper itself

Abstract

Inhibition of protein kinase C (PKC) activity in transformed cells and tumor cells containing activated p21(RAS) results in apoptosis. To investigate the pro-apoptotic pathway induced by the p21(RAS) oncoprotein, we first identified the specific PKC isozyme necessary to prevent apoptosis in the presence of activated p21(RAS). Dominant-negative mutants of PKC, short interfering RNA vectors, and PKC isozyme-specific chemical inhibitors directed against the PKCdelta isozyme demonstrated that PKCdelta plays a critical role in p21(RAS)-mediated apoptosis. An activating p21(RAS) mutation, or activation of the phosphatidylinositol 3-kinase (PI3K) Ras effector pathway, increased the levels of PKCdelta protein and activity in cells, whereas inhibition of p21(RAS) activity decreased the expression of the PKCdelta protein. Activation of the Akt survival pathway by oncogenic Ras required PKCdelta activity. Akt activity was dramatically decreased after PKCdelta suppression in cells containing activated p21(RAS). Conversely, constitutively activated Akt rescued cells from apoptosis induced by PKCdelta inhibition. Collectively, these findings demonstrate that p21(RAS), through its downstream effector PI3K, induces PKCdelta expression and that this increase in PKCdelta activity, acting through Akt, is required for cell survival. The p21(RAS) effector molecule responsible for the initiation of the apoptotic signal after suppression of PKCdelta activity was also determined to be PI3K. PI3K (p110(C)(AAX), where AA is aliphatic amino acid) was sufficient for induction of apoptosis after PKCdelta inhibition. Thus, the same p21(RAS) effector, PI3K, is responsible for delivering both a pro-apoptotic signal and a survival signal, the latter being mediated by PKCdelta and Akt. Selective suppression of PKCdelta activity and consequent induction of apoptosis is a potential strategy for targeting of tumor cells containing an activated p21(RAS).

Indexed as

ApoptosisGene Expression Regulation, EnzymologicSignal TransductionAnimalsBALB 3T3 CellsCell SurvivalEnzyme ActivationGene ExpressionGenes, DominantIsoenzymesMiceMutationNeoplasmsNIH 3T3 CellsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsIsoenzymesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase C-deltaProtein Kinase InhibitorsProto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)RNA, Small Interfering

Identifiers

PMID17350960
PMCPMC3527128
OpenAlexW2015190128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.